BABY Chart by TradingView
|Curious about the determined Tel Aviv group behind Litchenwald your author decided to take a gander at their 'success' and that would be the recently listed RTO through Cannacord called Else Nutrition Holdings Inc. - BABY.v. Curious in that this group has appeared to make the rounds of virtually every brokerage house in Vancouver before landing with the total whores at Cannacord.|
What can we say about this co? Not much because it has no business to speak of. Minimal 'sales' and half the dough raised in 'subscription receipts' is already spoken for 3 months in. A body HAS TO WONDER what 9 (countem) high level executives actually 'do' on any given day.
This group is immediately suspect for having Litchenwald anywhere near them. They are either inherently crooked or fully incapable of any DD. It appears to not matter that much because what we appear to have here is another worthless scam going nowhere but down the tubes.
|The financials ALREADY beg disbelief. $790k in current liabilities with another $580k due to related parties. $ 3.3m loss, instantly, and these dogs very much need to be avoided.|
|There are 3 (countem) shells. |
A-Labs Capital I Corp. - Doron Cohen - firstname.lastname@example.org - Echelon dated August 31, 2018
A-Labs Capital II Corp. - Doron Cohen - email@example.com - Haywood dated October 22, 2018
A-Labs Capital IV Corp. - Chay Benahmou - firstname.lastname@example.org - Haywood dated June 7, 2019
Common thread? The first two have Litchenwald showing on the BoD. Those two have failed in their QTs. Number 3 has different directors, excluding Litchenwald. That QT has yet to close. ALL QTs involve multi-millions in 'subscription receipts' for a dodgy, fully unknown and possibly the same, acquisition. 'Doron' describes his vast knowledge of "Mobile Advertising, AdTech"
|A-Labs Capital II Corp. (TSXV: ALAB.P) announces that it has completed its initial public offering through its agent, Haywood Securities Inc., of 2,000,000 common shares of the Company at a price of $0.10 per common share for total gross proceeds of $200,000 pursuant to a prospectus dated December 17, 2018 filed with the British Columbia and Alberta Securities Commissions.|
The Company has received final acceptance to be listed as a Capital Pool Company (CPC) on the TSX Venture Exchange. The common shares of the Company are expected to commence trading on the TSXV at the opening of market on or about March 15, 2019 under the trading symbol “ALAB.P”. Tel Aviv resident Doron Cohen is CEO of A-Labs Capital I Corp. The Company's board of directors and management team is comprised of: Doron Cohen, Noah Herscovici (CFO), Michael Mire (Director), Bruce Rowlands (Director) and Konstantin Lichtenwald (Director).